Magnetic resonance imaging and expression of vascular endothelial growth factor in hepatocellular nodules in cirrhosis and hepatocellular carcinomas

Topics in Magnetic Resonance Imaging

Volumn 16, Issue 1, 2005, Pages 67-75

  Kanematsu, Masayuki ^a,c   Semelka, Richard C ^b   Osada, Shinji ^a   Amaoka, Nozomi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Angiogenesis; Cirrhosis; Gadolinium; Hepatocellular carcinoma; Immunohistochemistry; Liver; Magnetic resonance (MR); Molecular; Vascular endothelial growth factor (VEGF); Western blatting

Indexed keywords

GADOLINIUM; VASCULOTROPIN;

CLINICAL PRACTICE; CORRELATION ANALYSIS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER NODULE; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOLOGY; RETROSPECTIVE STUDY; REVIEW; UPREGULATION; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; STATISTICS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 31944434717     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rmr.0000191133.91603.d2     Document Type: Review

References (32)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol. 1999;237:1-30.
3. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology. 1995;22:983-993.
4. Yamane A, Seetharam L, Yamaguchi S, et al. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene. 1994;9:2683-2690.
5. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumors. Hepatology. 1996;23:455-464.
6. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68-77.
7. Ohmori S, Shiraki K, Sugimoto K, et al. High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum Pathol. 2001;32:1363-1370.
8. Monacci WT, Merril MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial factor in normal rat tissues. Am J Physiol. 1993;264:995-1002.
9. Genetech Inc. Product information of Avastin. Available at: http:// www.gene.com/gene/products/information/oncology/avastin/index.jsp. Accessed March 1, 2005.
10. Drevs J, Mross K, Fuxius S, et al. A phase I dose escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in patients with liver metastasis of advanced cancer [abstract]. Proc Am Soc Clin Oncol. 2001;20:398.
11. Thomas A, Morgan B, Rowark G, et al. Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer. Clin Cancer Res. 2001;7:48.
12. Yung WA, Friedman H, Jackson E, et al. A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma [abstract]. Proc Am Soc Clin Oncol. 2002;21:315.
13. George D, Jonasch E, Hart L, et al. A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas. Clin Cancer Res. 2001;7:548.
14. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003;21:3955-3964.
15. Kanematsu M, Semelka RC, Leonardou P, et al. Angiogenesis in hepatocellular nodules: correlation of MR imaging and vascular endothelial growth factor. J Magn Reson Imaging. 2004;20:426-434.
16. Kanematsu M, Osada S, Amaoka N, et al. Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings. AJR Am J Roentgenol. 2005;184:832-841.
17. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996;56:3004-3009.
18. El-Assal ON, Yamanoi A, Soda Y, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology. 1998;27:1554-1562.
19. Yamaguchi R, Yano H, Nakashima Y, et al. Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep. 2000;7: 725-729.
20. Kwak BK, Shim HJ, Park ES, et al. Hepatocellular carcinoma: correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography. Invest Radiol. 2001;36:487-492.
21. Jeng KS, Sheen IS, Wang YC, et al. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection? World J Gastroenterol. 2004;10:676-681.
22. Ng IO, Poon RT, Lee JM, et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol. 2001;116:838-845.
23. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
24. Mukhopadhyay D, Tsiokas L, Zhou XM, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995;375:577-581.
25. von Marschall Z, Cramer T, Hocker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut. 2001;48:87-96.
26. Ishikawa K, Mochida S, Mashiba S, et al. Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis. Biochem Biophys Res Commun. 1999;254:587-593.
27. Matsui O, Kadoya M, Kameyama T, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991; 178:493-497.
28. Blancher C, Moore JW, Talks KL, et al. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000;60:7106-7113.
29. Kanematsu M, Osada S, Amaoka N, et al. Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with angiographically assisted CT. AJR Am J Roentgenol. 2004;183:1585-1593.
30. Yoshikawa J, Matsui O, Takashima T, et al. Fatty metamorphosis in hepatocellular carcinoma: radiologie features in 10 cases. AJR Am J Roentgenol. 1988;151:717-720.
31. Kutami R, Nakashima Y, Nakashima O, et al. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol. 2000;33:282-289.
32. Scarfo LM, Weller PF, Farber HW. Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. Am J Physiol Heart Circ Physiol. 2001;280:294-301.